# Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease

> **NCT00058773** · PHASE1 · TERMINATED · sponsor: **Baylor College of Medicine** · enrollment: 5 (actual)

## Conditions studied

- Hodgkin Disease
- Non-Hodgkins Lymphoma

## Interventions

- **DRUG:** Infusion of EBV Specific Cytotoxic T-Lymphocytes

## Key facts

- **NCT ID:** NCT00058773
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1996-01
- **Primary completion:** 2002-04
- **Final completion:** 2006-08
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2012-11-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00058773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00058773, "Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00058773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*